Zymeworks Inc.
ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
Last updated:
Abstract:
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
Status:
Application
Type:
Utility
Filling date:
23 Jul 2021
Issue date:
2 Dec 2021